206 related articles for article (PubMed ID: 32877803)
41. Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
Thorsell AG; Ekblad T; Karlberg T; Löw M; Pinto AF; Trésaugues L; Moche M; Cohen MS; Schüler H
J Med Chem; 2017 Feb; 60(4):1262-1271. PubMed ID: 28001384
[TBL] [Abstract][Full Text] [Related]
42. Tankyrase as a Novel Molecular Target in Cancer and Fibrotic Diseases.
Lakshmi TV; Bale S; Khurana A; Godugu C
Curr Drug Targets; 2017; 18(10):1214-1224. PubMed ID: 27425647
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of Epstein-Barr virus OriP function by tankyrase, a telomere-associated poly-ADP ribose polymerase that binds and modifies EBNA1.
Deng Z; Atanasiu C; Zhao K; Marmorstein R; Sbodio JI; Chi NW; Lieberman PM
J Virol; 2005 Apr; 79(8):4640-50. PubMed ID: 15795250
[TBL] [Abstract][Full Text] [Related]
44. Pleiotropic roles of tankyrase/PARP proteins in the establishment and maintenance of human naïve pluripotency.
Zimmerlin L; Zambidis ET
Exp Cell Res; 2020 May; 390(1):111935. PubMed ID: 32151493
[TBL] [Abstract][Full Text] [Related]
45. Zinc binding catalytic domain of human tankyrase 1.
Lehtiö L; Collins R; van den Berg S; Johansson A; Dahlgren LG; Hammarström M; Helleday T; Holmberg-Schiavone L; Karlberg T; Weigelt J
J Mol Biol; 2008 May; 379(1):136-45. PubMed ID: 18436240
[TBL] [Abstract][Full Text] [Related]
46. The Poly(ADP-ribose) Polymerase Enzyme Tankyrase Antagonizes Activity of the β-Catenin Destruction Complex through ADP-ribosylation of Axin and APC2.
Croy HE; Fuller CN; Giannotti J; Robinson P; Foley AVA; Yamulla RJ; Cosgriff S; Greaves BD; von Kleeck RA; An HH; Powers CM; Tran JK; Tocker AM; Jacob KD; Davis BK; Roberts DM
J Biol Chem; 2016 Jun; 291(24):12747-12760. PubMed ID: 27068743
[TBL] [Abstract][Full Text] [Related]
47. Tankyrase Sterile α Motif Domain Polymerization Is Required for Its Role in Wnt Signaling.
Riccio AA; McCauley M; Langelier MF; Pascal JM
Structure; 2016 Sep; 24(9):1573-81. PubMed ID: 27499439
[TBL] [Abstract][Full Text] [Related]
48. Sighting of tankyrase inhibitors by structure- and ligand-based screening and in vitro approach.
Kirubakaran P; Arunkumar P; Premkumar K; Muthusamy K
Mol Biosyst; 2014 Oct; 10(10):2699-712. PubMed ID: 25091558
[TBL] [Abstract][Full Text] [Related]
49. The C. elegans gene pme-5: molecular cloning and role in the DNA-damage response of a tankyrase orthologue.
Gravel C; Stergiou L; Gagnon SN; Desnoyers S
DNA Repair (Amst); 2004 Feb; 3(2):171-82. PubMed ID: 14706351
[TBL] [Abstract][Full Text] [Related]
50. Regulation of Wnt/β-catenin signalling by tankyrase-dependent poly(ADP-ribosyl)ation and scaffolding.
Mariotti L; Pollock K; Guettler S
Br J Pharmacol; 2017 Dec; 174(24):4611-4636. PubMed ID: 28910490
[TBL] [Abstract][Full Text] [Related]
51. The telomeric PARP, tankyrases, as targets for cancer therapy.
Seimiya H
Br J Cancer; 2006 Feb; 94(3):341-5. PubMed ID: 16421589
[TBL] [Abstract][Full Text] [Related]
52. Screening and structural analysis of flavones inhibiting tankyrases.
Narwal M; Haikarainen T; Fallarero A; Vuorela PM; Lehtiö L
J Med Chem; 2013 May; 56(9):3507-17. PubMed ID: 23574272
[TBL] [Abstract][Full Text] [Related]
53. Structural basis and sequence rules for substrate recognition by Tankyrase explain the basis for cherubism disease.
Guettler S; LaRose J; Petsalaki E; Gish G; Scotter A; Pawson T; Rottapel R; Sicheri F
Cell; 2011 Dec; 147(6):1340-54. PubMed ID: 22153077
[TBL] [Abstract][Full Text] [Related]
54. Structural and functional analysis of parameters governing tankyrase-1 interaction with telomeric repeat-binding factor 1 and GDP-mannose 4,6-dehydratase.
Eisemann T; Langelier MF; Pascal JM
J Biol Chem; 2019 Oct; 294(40):14574-14590. PubMed ID: 31375564
[TBL] [Abstract][Full Text] [Related]
55. The binding mechanism of a novel nicotinamide isostere inhibiting with TNKSs: a molecular dynamic simulation and binding free energy calculation.
Feng TT; Zhang YJ; Chen H; Fan S; Han JG
J Biomol Struct Dyn; 2016; 34(3):517-28. PubMed ID: 25933061
[TBL] [Abstract][Full Text] [Related]
56. Tankyrase (PARP5) Inhibition Induces Bone Loss through Accumulation of Its Substrate SH3BP2.
Mukai T; Fujita S; Morita Y
Cells; 2019 Feb; 8(2):. PubMed ID: 30813388
[TBL] [Abstract][Full Text] [Related]
57. Small-Molecule Inhibitors of Tankyrases as Prospective Therapeutics for Cancer.
Yu M; Yang Y; Sykes M; Wang S
J Med Chem; 2022 Apr; 65(7):5244-5273. PubMed ID: 35306814
[TBL] [Abstract][Full Text] [Related]
58. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.
Waaler J; Machon O; Tumova L; Dinh H; Korinek V; Wilson SR; Paulsen JE; Pedersen NM; Eide TJ; Machonova O; Gradl D; Voronkov A; von Kries JP; Krauss S
Cancer Res; 2012 Jun; 72(11):2822-32. PubMed ID: 22440753
[TBL] [Abstract][Full Text] [Related]
59. Proteomic Analysis of the Human Tankyrase Protein Interaction Network Reveals Its Role in Pexophagy.
Li X; Han H; Zhou MT; Yang B; Ta AP; Li N; Chen J; Wang W
Cell Rep; 2017 Jul; 20(3):737-749. PubMed ID: 28723574
[TBL] [Abstract][Full Text] [Related]
60. Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors.
Bregman H; Chakka N; Guzman-Perez A; Gunaydin H; Gu Y; Huang X; Berry V; Liu J; Teffera Y; Huang L; Egge B; Mullady EL; Schneider S; Andrews PS; Mishra A; Newcomb J; Serafino R; Strathdee CA; Turci SM; Wilson C; DiMauro EF
J Med Chem; 2013 Jun; 56(11):4320-42. PubMed ID: 23701517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
